JNJ - Johnson & Johnson

NYSE - NYSE Delayed price. Currency in USD
127.80
-1.31 (-1.01%)
At close: 4:00PM EDT

127.50 -0.30 (-0.23%)
Pre-market: 7:11AM EDT

Stock chart is not supported by your current browser
Previous close129.11
Open128.81
Bid127.08 x 800
Ask128.17 x 1100
Day's range127.17 - 129.05
52-week range118.62 - 148.32
Volume7,152,355
Avg. volume6,590,496
Market cap342.779B
Beta0.54
PE ratio (TTM)282.74
EPS (TTM)0.45
Earnings date16 Oct 2018
Forward dividend & yield3.60 (2.86%)
Ex-dividend date2018-05-25
1y target est143.45
Trade prices are not sourced from all markets
  • J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod
    Zacks14 hours ago

    J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod

    The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.

  • Healthcare ETFs in Focus Following JNJ Q2 Results
    Zacks22 hours ago

    Healthcare ETFs in Focus Following JNJ Q2 Results

    Investors should closely watch the movement of the Johnson & Johnson and keep a close eye on ETFs having double-digit allocation to this diversified drug maker.

  • Stock Market News For Jul 18, 2018
    Zacks22 hours ago

    Stock Market News For Jul 18, 2018

    Markets closed sharply higher on Tuesday, led by a rally in tech stocks.

  • J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)
    Zacksyesterday

    J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)

    A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

  • Asian stocks rise as solid US performance lifts spirits
    Associated Pressyesterday

    Asian stocks rise as solid US performance lifts spirits

    SINGAPORE (AP) — Asian markets climbed higher on Wednesday as a sweep of positive news from Wall Street and beyond boosted confidence in the U.S. economy.

  • Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch
    Zacksyesterday

    Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch

    Shares of Novartis (NVS) added just 0.14% during regular hours Tuesday, the last day of trading before the pharma giant releases its latest quarterly earnings report. Here's what to expect tomorrow morning.

  • What's Behind Johnson & Johnson's Double-Digit Growth?
    Motley Foolyesterday

    What's Behind Johnson & Johnson's Double-Digit Growth?

    Currency and acquisition tailwinds aside, the company has a slate of fast-growing drugs in its quiver.

  • What Happened in the Stock Market Today
    Motley Fool2 days ago

    What Happened in the Stock Market Today

    On a day stocks climbed following optimistic comments by the chairman of the Federal Reserve, Netflix reported disappointing subscriber additions, and Johnson & Johnson rose on strong pharmaceuticals sales.

  • Barrons.com2 days ago

    After the Bell: Dow Rises 56 Points as Stocks Keep Chugging Higher

    Stocks notched another day of gains on Tuesday, on a day when there was little in the way of market-moving news. The Dow Jones Industrial Average gained 55.53 points, or 0.22%, to 25,119.89, while the S&P 500 is up 11.12 points, or 0.40%, to 2809.55 and the Nasdaq Composite added 49.40 points, or 0.63%, to 7855.12. Part of it may have been a "no news is good news," sort of mentality, as Federal Reserve Chief Jerome Powell's dry testimony before the Senate Banking Committee seemed to indicate that the Central Bank was committed to staying the course and markets largely shrugged off earnings reports on a relatively quiet day.

  • Associated Press2 days ago

    Johnson & Johnson climbs while Netflix and UnitedHealth slip

    Stocks that moved substantially or traded heavily Tuesday: Netflix Inc., down $21 to $379.48 The streaming video company's second-quarter subscriber gains were weaker than analysts expected. Johnson & ...

  • Markets Right Now: Tech, health care lead gains for stocks
    Associated Press2 days ago

    Markets Right Now: Tech, health care lead gains for stocks

    NEW YORK (AP) — The latest on developments in financial markets (all times local):

  • J&J's (JNJ) Phase III Study for Invokana Halted Earlier
    Zacks2 days ago

    J&J's (JNJ) Phase III Study for Invokana Halted Earlier

    Johnson & Johnson's (JNJ) phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana is being stopped early based on positive pre-specified efficacy data.

  • J&J Nears Sale of Sylvant to U.K. Drugmaker Eusa Pharma
    Bloomberg2 days ago

    J&J Nears Sale of Sylvant to U.K. Drugmaker Eusa Pharma

    A unit of U.S. health-care giant Johnson & Johnson has agreed to sell global rights to a treatment for a rare blood disorder to Britain’s Eusa Pharma. Eusa Pharma is buying the rights to the drug Sylvant from Janssen Sciences Ireland UC for $115 million in cash, the Hemel Hempstead, England-based company said Wednesday, confirming a Bloomberg report. Eusa Pharma is working to focus its operations fully on treatments for oncology and rare diseases.

  • Johnson & Johnson (JNJ) Q2 2018 Earnings Conference Call Transcript
    Motley Fool2 days ago

    Johnson & Johnson (JNJ) Q2 2018 Earnings Conference Call Transcript

    JNJ earnings call for the period ending June 30, 2018.

  • Barrons.com2 days ago

    J&J Earnings: No More Tears?

    Shares of Johnson & Johnson (JNJ) are higher on Tuesday on the heels of the drug and personal products maker's second-quarter earnings, and although they're on track for their best day since early 2016, the stock is still lodged in the red for the year to date. The division saw sales jump 20%, helping to offset the performance of J&J’s consumer segment, which saw U.S. revenue decline 0.7%. J&J stock is on track to log its biggest percentage increase since the start of 2016.  It's a far cry from  last week, when a jury awarded $4.69 billion in damages to cancer patients who used J&J's talc products, sending the shares lower.

  • Johnson & Johnson beats revenue, profit projections for 2Q
    Associated Press2 days ago

    Johnson & Johnson beats revenue, profit projections for 2Q

    Fueled by a 20 percent sales jump in its prescription drugs business, Johnson & Johnson posted a 3 percent increase in second-quarter profit. J&J's prescription medicine business, which had lagged its medical device business until a couple years ago, accounted for half its $20.83 billion in total revenue.

  • J&J's (JNJ) Q2 Earnings Beat on Higher Cancer Drug Sales
    Zacks2 days ago

    J&J's (JNJ) Q2 Earnings Beat on Higher Cancer Drug Sales

    J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it narrows its full year sales forecast due to currency factors.

  • Watch Out For Goldman
    Zacks2 days ago

    Watch Out For Goldman

    Watch Out For Goldman

  • Goldman Beats in Blankfein's Final Quarter
    Zacks2 days ago

    Goldman Beats in Blankfein's Final Quarter

    Goldman Sachs (GS) CEO and Chairman Lloyd Blankfein announced his replacement this morning as the company he's run for the past 12 years easily beat earnings and revenue projections in its Q2 report.

  • Tech Stocks Lead Declines As Netflix Topples; Market Awaits Powell
    Investor's Business Daily2 days ago

    Tech Stocks Lead Declines As Netflix Topples; Market Awaits Powell

    Netflix led tech stocks lower early Tuesday as Johnson & Johnson, Goldman Sachs and UnitedHealth Group reported and markets looked toward Senate testimony from Fed Chief Powell.

  • J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)
    Zacks2 days ago

    J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)

    A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

  • Is Johnson & Johnson a Buy?
    Motley Fool2 days ago

    Is Johnson & Johnson a Buy?

    The healthcare giant has stumbled lately, but J&J still has plenty to offer investors.

  • Barrons.com2 days ago

    Morning Movers: Johnson & Johnson Gains; Deere, Caterpillar Slip

    The Dow Jones Industrial Average is edging lower this morning as UnitedHealth Group (UNH) slips on earnings. If so it will have to come from something we haven't seen yet, like Fed Chairman Jerome Powell's testimony before Congress. As for Powell, Nick Colas, co-founder of DataTrek Research, contends that he will want to convince the market that the Fed will raise rates two more times this year, a one-hike-per-quarter pace.

  • J&J (JNJ) Down on Trimmed View Despite Q2 Earnings Beat
    Zacks2 days ago

    J&J (JNJ) Down on Trimmed View Despite Q2 Earnings Beat

    J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it tightens its previously issued earnings guidance for 2018 while lowering its sales range.

  • Johnson & Johnson Reports Strong Second-Quarter Results
    Market Realist2 days ago

    Johnson & Johnson Reports Strong Second-Quarter Results

    Johnson & Johnson Reports Strong Second-Quarter ResultsJohnson & Johnson’s second-quarter earnings